Pregled bibliografske jedinice broj: 816246
IAEA randomised study on optimization of treatment of locally advanced NSCLC using radiotherapy and chemotherapy
IAEA randomised study on optimization of treatment of locally advanced NSCLC using radiotherapy and chemotherapy // Radiotherapy and oncology, 116 (2015), 1; 21-26 doi:10.1016/j.radonc.2015.06.017 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 816246 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
IAEA randomised study on optimization of treatment of locally advanced NSCLC using radiotherapy and chemotherapy
Autori
Jeremić, Branislav ; Fidarova, Elena ; Sharma, V. ; Faheem, M. ; Ameira, A. ; Nasr, Ben Amar ; Frobe, Ana ; Lau, F.N. ; Brincat, S. ; Jones, G.
Izvornik
Radiotherapy and oncology (0167-8140) 116
(2015), 1;
21-26
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
NSCLC ; locally advanced nonsmall cell lung canc ; radiotherapy ; chemotherapy ; randomized trial ; International Atomic Energy Agency
Sažetak
O optimize palliation in incurable locally advanced non-small cell lung cancer (NSCLC), the International Atomic Energy Agency conducted a prospective randomized study (NCT00864331) comparing protracted palliative radiotherapy (RT) course with chemotherapy (CHT) followed by short-course palliative RT. Treatment-naive patients with histologically confirmed NSCLC, stage IIIA/IIIB, received either 39 Gy in 13 fractions as RT alone (arm A, n = 31) or 2–3 platinum-based CHT cycles followed by 10 Gy in a single fraction or 16 Gy in 2 fractions separated by one week (arm B, n = 34). Primary outcome was overall survival. Treatment groups were balanced with respect to various variables. Median survival for all 65 patients was 8 months, while median survival was 7.1 and 8.1 months for the two arms, respectively (log-rank p = 0.4 by study arm, and p = 0.6 by Cox regression and stratified by country and sub-stage). One and three year survival rates for the two arms were 29%, and 9% and 41%, and 6%, respectively. There were no differences in any of the following endpoints: any failure, local failure, regional failure, contralateral thoracic failure, and distant failure between the two arms. High-grade (⩾3) toxicity was similar between the two arms. Symptoms, adverse events of any kind, KPS and body-mass index, were not different during treatment and during follow-up. There was no grade 5 toxicity. This incomplete and underpowered trial only hinted similar outcome between the treatment arms. Therefore, combined CHT-RT can perhaps be considered, in limited resource setting, where access to RT remains inadequate.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- CA Search (Chemical Abstracts)
- EMBASE (Excerpta Medica)
- Elsevier BIOBASE